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PURPOSE. To identify eyes of patients with diabetes type 2 that show progression of retinal
disease within a 1-year period using noninvasive techniques.
METHODS. Three hundred seventy-four type 2 diabetic patients with mild nonproliferative
diabetic retinopathy (Early Treatment Diabetic Retinopathy Study [ETDRS] level 20 or 35)
were included in a 12-month prospective observational study to identify retinopathy
progression. Four visits were scheduled at 0, 3, 6, and 12 months. Microaneurysm (MA)
activity using the RetmarkerDR and retinal thickness using spectral-domain optical coherence
tomography (SD-OCT) were assessed by a central reading center at all visits and ETDRS
severity level in the first and last visits.
RESULTS. Three hundred thirty-one eyes/patients completed the study. Microaneurysm formation
rate greater than or equal to 2 was present in 68.1% of the eyes and MA turnover greater than or
equal to 6 in 54.0% at month 6. Higher MA turnover values were registered in eyes that showed
progression in ETDRS severity level (P< 0.03). There were also significant correlations between
increased microaneurysm activity and increases in retinal thickness. Spectral-domain OCT
identified clinical macular edema in 24 eyes/patients (6.7%) and subclinical macular edema in
104 eyes/patients (28.9%) at baseline. Progression of retinal thickening was registered in eyes
that had either subclinical or clinical macular edema at baseline.
CONCLUSIONS. Changes in MA activity measured with RetmarkerDR and in central retinal
thickness in eyes with mild nonproliferative diabetic retinopathy and diabetes type 2 are able
to identify eyes at risk of progression. These eyes/patients should be selected for inclusion in
future clinical trials of drugs targeted to prevent diabetic retinopathy progression to vision-
threatening complications. (ClinicalTrials.gov number, NCT01145599.)
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type 2
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Diabetic retinopathy (DR) is a common and seriousophthalmic condition. It is the leading cause of blindness
among working age adults in the United States.1 Disability
consequent to vision loss related to eye disease among people
with diabetes threatens independence and can lead to reduced
quality of life.2
However, the rate of progression and risk for vision loss
appears to vary widely between patients despite similar
metabolic control.3
Therefore, the identification of different DR phenotypes
characterized by different dominant retinal pathology and
different rates of progression to vision-threatening retinopathy
and vision loss including center-involved macular edema, is of
major relevance for personalized management of DR and for
clinical trial design and patient selection.3 The inclusion of
eyes/patients in a clinical trial that do not progress during the
period of the trial makes it impractical to enroll the required
number of patients to detect differences in efficacy between
the drug being tested and the placebo.4
It is therefore of great interest to identify and characterize
eyes/patients that show disease activity and are at higher risk
for developing vision-threatening retinopathy. The aim of this
1-year multicenter observational study was to identify progres-
sion in patients with mild nonproliferative DR (NPDR) by
evaluating repeated noninvasive routine tests such as color
fundus photography (CFP) and spectral-domain optical coher-
ence tomography (SD-OCT).
METHODS
Patients
This was a prospective, multicenter, observational study,
designed to follow eyes/patients with mild NPDR (20 and 35
of the Early Treatment Diabetic Retinopathy Study [ETDRS]
classification) for a period of 1 year. The study was an
investigator-driven observational study sponsored by the
European Vision Institute Clinical Research Network (provided
in the public domain by EVICR.net).5,6
A total of 374 patients were recruited between September
2010 and June 2012 in 19 European clinical sites and followed
over a 1-year period. Men and women with diagnosed adult-
onset type 2 diabetes, age 35 to 82 years, mild NPDR (20 and
35 of ETDRS classification), best corrected visual acuity (BCVA)
greater than or equal to 75 letters (‡20/32) and refraction with
spherical equivalent less than 65 diopters (D) were included
in the study. Exclusion criteria included the presence of
cataract or other eye disease that may interfere with fundus
examination, glaucoma, other retinal disease, any eye surgery
within a period of 6 months, dilatation of the pupil less than 5
mm and previous or requiring treatment for DR at screening.
All patients gave written consent. The tenets of the Declaration
of Helsinki were followed and approval was obtained from
each institutional review board (ClinicalTrials.gov Identifier:
NCT01145599).
At baseline visit, patients’ body weight, height, blood
pressure, and concomitant medication were recorded. Based
on the inclusion/exclusion criteria, one eye per patient was
selected by the physician as the study eye. When both eyes
fulfilled the same criteria, one of the eyes was selected by
choosing sequentially the left or the right eye.
Patients performed four study visits: V0 (month 0), V3
(month 3), V6 (month 6), and V12 (month 12). At each visit,
the study eyes underwent a complete ophthalmic examination,
which included BCVA, slit-lamp examination, IOP measure-
ments, digital fundus photography (CFP), and SD-OCT. Data on
diabetes systemic medication, blood pressure measurements,
HbA1c levels, and body mass index (BMI) values were
collected.
A central reading center (CORC-Coimbra Ophthalmology
Reading Center, Portugal) classified the CFP for ETDRS grading
and microaneurysms (MA) activity and the SD-OCT images.
During the period of the study and outside of the study
visits, patients were followed in the clinical centers according
to usual clinical practice. Identification of clinically significant
macular edema (CSME) was based on ETDRS criteria.7,8
Color Fundus Photography
Color fundus photography was performed according to the
ETDRS protocol at the first and last visits. The seven-field
photographs were obtained at 308/358 for DR classification
according to ETDRS grading scale.7 The grading of ETDRS
levels was performed by double grading, with an intergrader
reproducibility of 87% (j ¼ 0.84) for sublevels of ETDRS and
93% (j¼ 0.91) for one step ETDRS level. Considering MAs and
hard exudates, the more frequent alterations present in the
eyes graded in this study, the intergrader reproducibility is 90%
(j ¼ 0.75) for MA and 83% (j ¼ 0.71) for hard exudates.
Additionally, 458/508 field-2 color fundus images (macula) were
taken at all visits for automated MA analysis, using an
automated computer-aided diagnostic system (RetmarkerDR,
Retmarker SA, Coimbra, Portugal) at the reading center.
RetmarkerDR is a patented computer software certified as a
CE mark Class IIa medical device (European Union Certifica-
tion of Conformity). The software was trained and tested prior
to the CE medical device classification, that is, the algorithm
(including the classifier) is objective and reproducible, it is not
modified or retrained to any individual dataset.
This automated computer-aided diagnostic system consists
of software earmarking MAs; it includes a coregistration
algorithm that allows comparison within the same retinal
location between different visits for the same eye.
RetmarkerDR calculates for each eye/patient the number of
MA in each visit and the number of MAs that appear and/or
disappear from one visit to the other, allowing calculation of
the number of MA appearing and/or disappearing per time
interval (i.e., the MA formation rate and the MA disappearance
rate, respectively). The MA turnover is computed as the sum of
the MA formation and MA disappearance rates.9–11
Previous work from our group9,12 showed a good inter-
grader agreement for the total number of MAs earmarked and
the MA turnover for three independent human graders.
The RetmarkerDR shows a similar intergrader agreement for
the total number of MAs, MA formation rate, and MA turnover
(when compared with a human grader, intraclass correlation
coefficients were 0.857 and 0.806, respectively) while showing
no intragrader variability as opposed to human graders, being,
therefore, a reliable tool for MA assessment.
In this study, the MA formation rate and MA turnover were
computed for all the eyes/patients at months 3, 6, and 12 (V3,
V6, and V12, respectively). Patients were thereafter classified
based on the presence of MA formation rate greater than or
equal to 2, according to Nunes et al.12 and on the presence of a
MA turnover greater than or equal to 63, according to Nunes et
al.3 An independent verification was also achieved by revisiting
the CALDIRET data.11
These cut-off values have been proposed as predictive of
progression of diabetic retinopathy.3,11,12
Optical Coherence Tomography
Spectral-domain OCT was performed using Cirrus (n ¼ 194;
Carl Zeiss Meditec, Inc., Dublin, CA, USA), Spectralis (n¼ 166;
Heidelberg Engineering, Heidelberg, Germany), Copernicus (n
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¼ 4; Optopol, Zawiercie, Poland), or three-dimensional (3D)
OCT-1000 (n¼ 10; Topcon Corporation, Tokyo, Japan).
Retinal thickness (RT) in the central subfield (central area
with 1 mm in diameter), and the four areas of the inner and
outer rings (within 1–3 mm and 3–6 mm, respectively) were
collected. Only Cirrus and Spectralis SD-OCT data are reported
(n ¼ 360), because of availability of normative data and the
number of patients examined. The data from these instruments
were analyzed independently.
To identify eyes/patients with increased RT in the central
subfield (clinical and subclinical macular edema) and in the
inner and outer rings, the reference values established by
DRCR.net were used:
For clinical macular edema (ClinicalTrials.gov Identifier:
NCT01909791)13:
1. Retinal thickness greater than or equal to 290 lm in
women and greater than or equal to 305 lm in men for
Cirrus SD-OCT; and
2. Retinal thickness greater than or equal to 305 lm in
women and greater than or equal to 320 lm in men for
Spectralis SD-OCT.
For subclinical macular edema14–16:
1. Retinal thickness greater than 260 lm and less than 290
lm in women and greater than 275 lm and less than
305 lm in men, for Cirrus SD-OCT; and
2. Retinal thickness greater than 275 lm and less than 305
lm in women and greater than 290 lm and less than
320 lm in men for Spectralis SD-OCT.
For the inner and outer rings (ClinicalTrials.gov Identifier:
NCT01331005):
1. Normal RT, if there was no more than one area above
normal range (normal meanþ 2 SD) and no area 15 lm
above normal range; and
2. Increased RT, if there was at least two areas above normal
range and/or one area 15 lm above normal range.
The nine SD-OCT areas were classified as decreased,
normal, or increased relatively to available Cirrus normative
data. Because no normative database is available for Spectralis
SD-OCT, a scaling factor was used based on analysis of 113
eyes/patients that performed both Cirrus and Spectralis SD-
OCT in the study. The RT values were higher with Spectralis
SD-OCT: þ16.6 lm for the central subfield, þ18.1 lm for the
inner ring, and þ17.7 lm for the outer ring. Based on these
differences, RT values of Spectralis SD-OCT were scaled to
Cirrus SD-OCT considering18 lm in inner and outer ring. For
the central subfield the mean difference between Spectralis
and Cirrus SD-OCT of 15 lm reported by the DRCR.net was
taken into account.
Sample Size
To characterize retinal disease progression in type 2 diabetic
patients with early NPDR a sample size minimum of 356 eyes/
patients was estimated based on the MA turnover results
published by Nunes et al.12 for a statistical power of 90%, an a
level of 0.05 and a drop-out of 10% (i.e., considering that 60%
of the patients with a MA formation rate ‡ 2 will develop CSME
in a 2 years’ time interval and that only 20% of the patients with
mild NPDR will have a MA formation rate ‡ 2).
Data Analysis
Categorical variables are summarized with frequencies and
percentages and numerical variables with mean and SD.
To test statistically significance differences at baseline
between eyes/patients included and dropped out of the study
a univariate analysis was performed with Bonferroni correction
of the P value. The v2 test was used for categorical variables,
and the Student’s t-test or the nonparametric Mann-Whitney U
tests were used for continuous variables.
To compare the average evolution between visits of MA
parameters (formation rate and turnover) and RT parameters
the repeated measures ANOVA was performed.
To analyze associations between continuous variables the
Pearson correlation was computed.
All statistical analyses were performed with STATA version
12.1 (StataCorp LP, College Station, TX, USA), and P values less
or equal than 0.05 were considered statistically significant
results.
RESULTS
From the 374 patients/eyes enrolled in the study (174 left eyes
and 200 right eyes), 331 completed the study, that is,
completed the 1-year follow-up period or developed CSME
(ETDRS criteria) needing treatment (three eyes/patients). Two
patients deceased between baseline and the last visit and 41
withdrew from the study (Fig.).
Baseline characteristics of patients enrolled in the study are
presented in Table 1.
No statistically significant differences were found at
baseline between the eyes/patients included in the study and
the 43 eyes/patients that dropped out of the study.
Three eyes/patients were diagnosed with CSME during the
1-year follow-up period, all males, age ranging from 61 to 72
years and with HbA1c levels ranging from 5.9% to 8.5%. The
ETDRS level was 35C for one eye/patient and 35D for the other
2. All three eyes had a MA formation rate at month 3 greater
than or equal to 2 and a MA turnover greater than or equal to 6.
One of three patients had at baseline the OCT criteria for
macular edema (central subfield > 305 lm; Cirrus SD-OCT).
Twenty three eyes/patients showed an increase in ETDRS
level from screening visit to V12 and 24 patients showed a
decrease in ETDRS level (Table 2).
Microaneurysm Parameters
Microaneurysm formation rate greater than or equal to 2 was
present in 68.1% [95% CI: 63.0%–73.1%] of the eyes and MA
turnover greater than or equal to 6 in 54.0% [95% CI: 48.5%–
59.4%] at V6.
The MA formation rate and MA turnover at V6 showed a
strong correlation with the values at V3 and V12. For the MA
formation rate the correlation between V12 and V3 was r ¼
0.950 (P < 0.001), and between V12 and V6 r ¼ 0.912 (P <
0.001). For the MA turnover the correlation between V12 and
V3 was r ¼ 0.957 (P < 0.001), and between V12 and V6 r ¼
0.937 (P < 0.001).
The results show that there is a correlation between MA
turnover values obtained at 6 and 12 months and changes in
ETDRS level.
For the 23 eyes/patients that showed an increase in ETDRS
level from baseline to V12, 39.1% had a MA turnover greater
than or equal to 6 at V6, whereas only 8.3% of the eyes/patients
that showed a decrease in ETDRS level had a MA turnover
greater than or equal to 6 (P¼ 0.013). At V12, 34.8% of the 23
eyes/patients that showed an increase in ETDRS level from
baseline to V12, had a MA turnover greater than or equal to 6,
whereas only 8.3% of the eyes/patients that showed a decrease
in ETDRS level had a MA turnover greater than or equal to 6 (P
¼ 0.027; Table 3).
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The MA parameters showed very weak, positive statistically
significant correlations with HbA1c levels and BMI (r < 0.181).
There was a very weak, positive statistically significant
correlation at V6 between MA parameters (number, formation
rate, and turnover) and the RT in the central subfield (r ¼
0.141, r¼0.170, and r¼0.156, respectively). For the inner and
outer ring areas statistically significant weak correlations were
also found for most of the respective areas and visits (for the
inner ring r < 0.193 and for the outer ring r < 0.328).
Associations were found between the MA formation rate
and MA turnover cut-off values (‡2 and ‡6, respectively) and
the presence of increased RT in the central subfield, inner and/
or outer ring:
1. Of the eyes/patients with an increased RT in the central
subfield, inner and/or outer ring, 61.8% (95% CI: 44.6%–
79.0%) to 76.7% (95% CI: 65.6%–87.7%) showed an MA
formation rate greater than or equal to 2 and/or an MA
turnover greater than or equal to 6; and
2. Of the eyes/patients with a MA formation rate less than 2
and/or a MA turnover less than 6, 81.3% (95% CI: 74.8%–
87.8%) to 87.7% (95% CI: 82.3%–90.1%) showed a normal
RT in the central subfield, inner and/or outer ring.
TABLE 1. Baseline Characteristics of the Eyes/Patients That Were Included and Dropped Out of the Study
Patients Included in the Study,
n ¼ 374
Drop-Out Patients,
n ¼ 43 P
Sex, female/male, frequency (%) 131 (35.0)/243 (65.0) 19 (44.2)/24 (55.8) 0.24
ETDRS level
20, frequency (%) 70 (18.7) 12 (27.9) 0.15
35, frequency (%) 304 (81.3) 31 (72.1)
Age, mean (SD), y 60.3 (9.0) 58.3 (9.89) 0.17
HbA1c, mean (SD), % 7.8 (1.5) 7.8 (1.5) 0.83
Systolic blood pressure, mean (SD), mm Hg 137.6 (16.6) 135.6 (17.8) 0.46
Diastolic blood pressure, mean (SD), mm Hg 77.4 (10.0) 81.1 (8.0) 0.02*
BMI, mean (SD), kg/m2 29.9 (5.4) 30.6 (5.4) 0.40
BCVA, mean (SD), letters 85.3 (4.6) 84.1 (5.0) 0.11
No. of MAs, mean (SD) 3.7 (5.4) 2.5 (3.5) 0.16
* Bonferroni corrected P value 0.006.
FIGURE. Consort flow chart.
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Finally, MA parameters obtained at V6 were the most
informative, indicating that the time interval of 6 months is
necessary to evaluate MA activity.
Retinal Thickness
Considering results obtained at baseline with the Cirrus and
the Spectralis and based on their respective normal database,
an increased RT in the central subfield was found in 9.8% (95%
CI: 5.6%–13.9%) when using the Cirrus and 10.8% (95% CI:
6.1%–15.6%) using Spectralis for a total of 10.3% of the eyes
examined, while a decreased RT was found in 1.5% (95% CI:
0%–3.3%) using the Cirrus and 9.6% (95% CI: 5.1%–14.1%)
using Spectralis for a total of 5.3% of the eyes (Table 4). In the
inner ring areas, this proportion was maintained. The highest
number of eyes showing increased RT was found in the outer
ring areas (13.3%–23.1%).
In the central subfield 24 eyes/patients (6.7%, correspond-
ing to 6.2% [95% CI: 2.8%–9.6%] with the Cirrus and 7.2% [95%
CI: 3.3%–11.2%] with the Spectralis) had a OCT diagnosis of
clinical macular edema, according to the DRCR.net standards
(Table 4).13 Subclinical macular edema was identified in 104
eyes/patients (28.9%, corresponding to 32.0% [95% CI: 25.4%–
38.5%] with the Cirrus and 25.3% [95% CI: 18.7%–31.9%] with
the Spectralis; Table 4).
Eyes/patients classified as subclinical and clinical macular at
baseline occurred in eyes/patients with ETDRS level 20 and 35,
respectively 8.3% and 25.9%.
No correlation was found between the eyes/patients that
showed an increase in ETDRS level at the end of 1 year of
follow-up and the eyes/patients that presented higher retinal
thickness values in the central subfield (i.e., subclinical and
clinical macular edema; P ¼ 0.61).
The eyes that showed increases in RT were in general the
same eyes during the entire follow-up period. Eighty-two percent
(82.9%) of the eyes with increased RT in the central subfield at
baseline had increased RT at V12. Increase in RT occurred also in
the inner ring (73.2%) and in the outer ring (72.8%).
Increase in central subfield RT over the 1-year follow-up
was registered in eyes that had subclinical and clinical macular
edema at baseline. In the eyes with clinical macular edema at
baseline the mean RT increase was 4.8 lm (95% CI:3.3 lm to
12.9 lm) for Cirrus SD-OCT and 7.63 lm (95% CI:25.5 lm to
40.8 lm) for Spectralis SD-OCT.
DISCUSSION
This 1-year, observational, longitudinal study of 374 patients
with diabetes type 2, mild NPDR (ETDRS levels 20 and 35) and
good visual acuity, examined at baseline and at 3, 6, and 12
months, by 19 clinical sites across Europe, showed that
changes in RT and MA activity vary widely between patients
with similar metabolic control, duration of disease and ETDRS
retinopathy severity level, confirming previous reports.3,12 T
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TABLE 2. Number of Eyes/Patients With ETDRS Changes From V0 to
V12
ETDRS
Level at V0
ETDRS Level at V12
Total10 15 20 35 43 47
20 1 1 0 19 0 0 21
35 2 0 20 0 3 1 26
Total 3 1 20 19 3 1 47
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Higher MA turnover values at V6 were found to be
associated with increase in ETDRS level at the end of the 1
year of follow-up, which supports previous reports that MA
turnover can identify eyes likely to progress.3,12
Regarding RT changes, it is of relevance that of the 360
eyes/patients (considering only those examined with Cirrus or
Spectralis SD-OCT) included in the study, center-involving
macular edema with indication for treatment based on OCT
values,13 was found to be present in 24 eyes (6.7%). These eyes
were not diagnosed on slit-lamp examination. There were also
104 eyes (28.9%) that met the OCT criteria for subclinical
macular edema.14–16
Microaneurysms parameters (number, formation rate, and
turnover) correlated with RT increases, with the strongest
correlations found with MA formation rate and MA turnover.
Automated image analysis of MA turnover is shown, in this
study, to identify retinal vascular disease activity at this
retinopathy stage, predicting ETDRS level changes and
showing also, correlations with increased RT (i.e., macular
edema).
It is also of note that when considering all the patients
included in the study, there was little progression in RT values
over the 1-year follow-up period. Progression was only found in
the eyes that already had thickness increases at baseline and
mainly in the central subfield. It is also noteworthy that the
changes identified in RT at baseline remained generally in the
same location during the entire period of follow-up. These
findings show that 1 year is a relatively short time interval for a
clinical trial testing therapies against increases in RT (i.e.,
retinal edema) unless only patients with increased RT in the
central subfield are selected for the trial. However, our
observations showed that RT measurements performed with
SD-OCT are reliable and may be followed accurately, and that
eyes with subclinical macular edema at baseline are good
candidates for clinical trials.
It is of interest that no significant correlation was found
between the presence of increased RT in the central subfield
and ETDRS levels 20 or 35.
There have been a number of reports in the literature,
suggesting that a decrease in RT attributed to a neurodegen-
erative process is a frequent finding in the early stages of
diabetic retinal disease.17,18 This observation is not confirmed
in our study. The number of eyes with abnormally increased RT
almost doubled the number of eyes with decreased RT.
This multicenter, multinational study demonstrated that
noninvasive procedures such as fundus photography and SD-
OCT are useful tools to monitor microvascular disease activity
and development of edema in the early stages of diabetes (mild
NPDR, ETDRS levels 20 and 35). The findings here described
TABLE 4. Frequency (Number and Percentage) of the Eyes/Patients
With Decreased/Normal/Increased RT at Baseline
Cirrus,
n ¼ 194
Spectralis,
n ¼ 166
Central subfield
Decreased (mean  2 SD) 3 (1.5) 16 (9.6)
Normal 172 (88.7) 132 (79.5)
Increased (mean þ 2 SD) 19 (9.8) 18 (10.8)
Inner ring
Nasal
Decreased (mean  2 SD) 7 (3.6) 28 (16.9)
Normal 168 (86.6) 124 (74.7)
Increased (mean þ 2 SD) 19 (9.8) 14 (8.4)
Increased (mean þ 2 SD
þ 15 lm) 5 (2.6) 2 (1.2)
Superior
Decreased (mean  2 SD) 5 (2.6) 26 (15.7)
Normal 168 (86.6) 123 (74.1)
Increased (mean þ 2 SD) 21 (10.8) 17 (10.2)
Increased (mean þ 2 SD
þ15 lm) 4 (2.1) 1 (0.6)
Temporal
Decreased (mean  2 SD) 7 (3.6) 26 (15.7)
Normal 167 (86.1) 118 (71.1)
Increased (mean þ 2 SD) 20 (10.3) 22 (13.3)
Increased (mean þ2 SD
þ15 lm) 5 (2.6) 4 (2.4)
Inferior
Decreased (mean  2 SD) 10 (5.2) 28 (16.9)
Normal 163 (84) 126 (75.9)
Increased (mean þ 2 SD) 21 (10.8) 12 (7.2)
Increased (mean þ 2 SD
þ 15 lm) 5 (2.6) 2 (1.2)
Outer ring
Nasal
Decreased (mean  2 SD) 6 (3.1) 13 (7.8)
Normal 158 (81.4) 135 (81.3)
Increased (mean þ 2 SD) 30 (15.5) 18 (10.8)
Increased (mean þ 2 SD
þ 15 lm) 10 (5.2) 0 (0.0)
Superior
Decreased (mean  2 SD) 9 (4.6) 9 (5.5)
Normal 158 (81.4) 120 (72.7)
Increased (mean þ 2 SD) 27 (13.9) 36 (21.8)
Increased (mean þ 2 SD
þ 15 lm) 7 (3.6) 0 (0.0)
Temporal
Decreased (mean  2 SD) 4 (2.1) 7 (4.2)
Normal 160 (82.5) 106 (63.9)
Increased (mean þ 2 SD) 30 (15.5) 53 (31.9)
Increased (mean þ 2 SD
þ 15 lm) 10 (5.2) 2 (1.2)
Inferior
Decreased (mean  2 SD) 8 (4.1) 9 (5.4)
Normal 162 (83.5) 118 (71.1)
Increased (mean þ 2 SD) 24 (12.4) 39 (23.5)
Increased (mean þ 2 SD
þ 15 lm) 6 (3.1) 0 (0.0)
TABLE 4. Continued
Cirrus,
n ¼ 194
Spectralis,
n ¼ 166
Central subfield
Subclinical macular edema 62 (32.0) 42 (25.3)
Clinical macular edema 12 (6.2) 12 (7.2)
Inner ring increased 23 (11.9) 19 (11.5)
Outer ring increased 36 (18.6) 40 (24.1)
1-year change (eyes/patients that
completed the study)
Subclinical to clinical macular
edema 5 of 52 7 of 38
Clinical to subclinical macular
edema 2 of 10 4 of 11
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contribute to improve our understanding of DR progression
and to improve the design of clinical trials aiming to test the
effect of drugs to prevent DR progression to vision-threatening
complications.
In conclusion, changes in MA activity measured with
RetmarkerDR on fundus photographies and in central RT
measured by SD-OCT show wide variations between different
patients with mild NPDR and diabetes type 2. It is possible,
using these noninvasive procedures, SD-OCT and fundus
photography, to identify the eyes that are at higher risk of
progression. These eyes/patients should be the ones selected
for inclusion in future clinical trials of drugs targeted to
prevent DR progression.
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